Potential prognostic biomarkers of pancreatic cancer

Pancreas

Volumn 43, Issue 1, 2014, Pages 22-27

  Chen, Kathryn T ^a   Kim, Phillip D ^a   Jones, Kelly A ^a   Devarajan, Karthik ^a   Patel, Bhavinkumar B ^a   Hoffman, John P ^a   Ehya, Hormoz ^a   Huang, Min ^a   Watson, James C ^a   Tokar, Jeffrey L ^a   Yeung, Anthony T ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

cyst fluid; mucin; pancreatic duct fluid; PDAC; proteomic biomarkers; S100

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN A; CALGRANULIN B; MUCIN; MUCIN 1; MUCIN 13; MUCIN 2; MUCIN 5AC; MUCIN 5B; MUCIN 6; PANCREAS ENZYME; UNCLASSIFIED DRUG;

AMPULLARY ADENOCARCINOMA; ARTICLE; BENIGN TUMOR; CANCER PROGNOSIS; CANCER STAGING; CARCINOMA IN SITU; CLINICAL ARTICLE; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GEL ELECTROPHORESIS HIGH PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; RECURRENT DISEASE; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY;

ADENOCARCINOMA, MUCINOUS; CALGRANULIN A; CALGRANULIN B; CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; HUMANS; KAPLAN-MEIER ESTIMATE; MASS SPECTROMETRY; MUCINS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891532755     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3182a6867e     Document Type: Article

References (31)

1. Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128:1626-1641. (Pubitemid 40692556)
2. Handrich SJ, Hough DM, Fletcher JG, et al. The natural history of the incidentally discovered small simple pancreatic cyst: long-term follow-up and clinical implications. AJR Am J Roentgenol. 2005;184:20-23. (Pubitemid 40040898)
3. Hellstrom M, Svensson MH, Lasson A. Extracolonic and incidental findings on CT colonography (virtual colonoscopy). AJR Am J Roentgenol. 2004;182:631-638. (Pubitemid 38269522)
4. Sahani DV, Kadavigere R, Saokar A, et al. Cystic pancreatic lesions: a simple imaging-based classification system for guiding management. Radiographics. 2005;25:1471-1484. (Pubitemid 41695317)
5. Testini M, Gurrado A, Lissidini G, et al. Management of mucinous cystic neoplasms of the pancreas. World J Gastroenterol. 2010;16:5682-5692.
6. Hwang JH, Voortman J, Giovannetti E, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PloS One. 2010;5:e10630.
7. Nagathihalli NS, Nagaraju G. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta. 2011;1816:209-218.
8. Takano S, Togawa A, Yoshitomi H, et al. Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy. Ann Surg Oncol. 2008;15:3157-3168.
9. Nedjadi T, Kitteringham N, Campbell F, et al. S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. Br J Cancer. 2009;101:1145-1154.
10. Phillips PA, Dudeja V, McCarroll JA, et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 2007;67:9407-9416. (Pubitemid 47535931)
11. Ke E, Patel BB, Liu T, et al. Proteomic analyses of pancreatic cyst fluids. Pancreas. 2009;38:e33-e42.
12. Ishihama Y, Oda Y, Tabata T, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics. 2005;4:1265-1272. (Pubitemid 41448714)
13. Li XM, Patel BB, Blagoi EL, et al. Analyzing alkaline proteins in human colon crypt proteome. J Proteome Res. 2004;3:821-833. (Pubitemid 39166244)
14. Searle BC. Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies. Proteomics. 2010;10:1265-1269.
15. Chen R, Pan S, Yi EC, et al. Quantitative proteomic profiling of pancreatic cancer juice. Proteomics. 2006;6:3871-3879. (Pubitemid 44065164)
16. Gronborg M, Bunkenborg J, Kristiansen TZ, et al. Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res. 2004;3:1042-1055. (Pubitemid 39425662)
17. Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008;8:241.
18. Vincent A, Perrais M, Desseyn JL, et al. Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. Oncogene. 2007;26:6566-6576. (Pubitemid 47530602)
19. Balague C, Audie JP, Porchet N, et al. In situ hybridization shows distinct patterns of mucin gene expression in normal, benign, and malignant pancreas tissues. Gastroenterology. 1995;109:953-964.
20. Jinfeng M, Kimura W, Hirai I, et al. Expression of MUC5AC and MUC6 in invasive ductal carcinoma of the pancreas and relationship with prognosis. Int J Gastrointest Cancer. 2003;34:9-18. (Pubitemid 38962756)
21. Yamazoe S, Tanaka H, Sawada T, et al. RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. J Exp Clin Cancer Res. 2010;29:53.
22. Hoshi H, Sawada T, Uchida M, et al. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer. Int J Oncol. 2011;38:619-627.
23. Mall AS, Tyler MG, Ho SB, et al. The expression of MUC mucin in cholangiocarcinoma. Pathol Res Pract. 2010;206:805-809.
24. Van Heek NT, Maitra A, Koopmann J, et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther. 2004;3:651-656. (Pubitemid 41351104)
25. Andrianifahanana M, Moniaux N, Schmied BM, et al. Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res. 2001;7:4033-4040. (Pubitemid 34044624)
26. Liddle RA. Regulation of cholecystokinin secretion by intraluminal releasing factors. Am J Physiol. 1995;269(3 pt 1):G319-G327.
27. O'Keefe SJ, Bennet WM, Zinsmeister AR, et al. Pancreatic enzyme synthesis and turnover in human subjects. Am J Physiol. 1994; 266(5 pt 1):G816-G821.
28. Dlugosz J, Folsch UR, Czajkowski A, et al. Feedback regulation of stimulated pancreatic enzyme secretion during intraduodenal perfusion of trypsin in man. Eur J Clin Invest. 1988;18:267-272.
29. Sunamura M, Lozonschi L, Takeda K, et al. Criteria for diagnosis of acute pancreatitis in Japan and clinical implications. Pancreas. 1998;16:243-249. (Pubitemid 28158024)
30. Kim HJ, Kang HJ, Lee H, et al. Identification of S100A8 and S100A9 as serologicalmarkers for colorectal cancer.JProteomeRes. 2009;8:1368-1379.
31. Gebhardt C, Nemeth J, Angel P, et al. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72:1622-1631. (Pubitemid 44666730)